Recent Finacing
Recent Raise
River Vision Development develops protein therapy RV001 for Graves’ orbitopathy and other indications, and is managed under contract by Narrow River Management to provide drug-development leadership.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
